Embed Size (px)
Citation preview
1
DIOPTERDRUG DELIVERY CONTACT LENS
TO TREAT EYE DISEASE
OIS@SECO
MARCH 2020
2
The Platform
Patented advanced drug-eluting contact lens
for multiple eye disease indications
Products:Glaucoma
Infection
Allergy
Rare Diseases
$B MarketsApproved
Contact LensApproved
Drugs
2
3
l Developing drug delivery contact lens
l Extensive patent portfolio covering the technology
l Initial markets: Glaucoma, Antibiotic Lens & Cystinosis (orphan indication)
l Completed phase I glaucoma studies – no adverse events
l Strong relationship with patient groups
l Raising $5M financing to continue development and for product launch in 2020
Background
3
4
MEMBER ROLE BACKGROUND
CHRISTOPHER ADAMS CEOCommercialized new corneal wound healing contact lens50,000 patients treatedRaised early stage financing
ANUJ CHAUHAN CTO
Professor and Department Head in Chemical Engineering at Colorado School of MinesInventor of drug delivery lens technologyInventor of ophthalmic technologies for other startups(TearClear)
CRAIG WALKER VPFormer VP of J&J Vision Care30 years of contact lens experienceDeveloped leading J&J brands, Oasis, Acuvue lenses
Team
5
Lens delivers drug directly to the cornea increasing bioavailability to at least 20x that for eye drops
Can deliver drug slowly so no need for multiple doses
Can treat diseases, correct vision & provide nutraceuticals
Many companies tried but could not design contacts for controlled release without impacting key properties
Cornea
Tear film
Drug-loadedcontact lens
Contact Lens Drug Delivery Advantages
6
Novel Diopter TechnologyDi f fu s ion Bar r ie r s Loaded Lenses
Lens
Polymer
Drug
h
Diffusion barrier Vitamin E
7
INDICATIONNO. OF PATIENTS
USROW
POTENTIAL ANNUAL REVENUE ($)
ANTIBIOTIC LENS 1ST PRODUCT – 2020 LAUNCH
75,000 10M 150M
GLAUCOMA 2ND PRODUCT 1,700,00 34M 200M
CYSTINOSIS (ORPHAN) 500 10,000 100M
POST SURGICAL PAIN 4,000,000 20M 200M
DRY EYE 20,000,000 120M 300M
Company has already developed lenses for each of these indications
using approved drugs.
Product Pipeline
8
12
14
16
18
20
22
24
26
0 50 100 150 200 250 300
IOP
(m
mH
g)
Time (hour)
Treated Eye
Untreated Eye
*Timolol & Dorzolamide (Cosopt)
*Drug Removed / Effect continues
Glaucoma Drug LensLowers I OP by 20% in An imal M odel
8
9
0
5
10
15
20
25
30
35
40
0 100 200 300 400 500 600
Bim
ato
pro
st m
ass
re
lea
se (
µg
)
Time (hrs)
Control Acuvue Oasys (35.56 μg) Acuvue Oasys VE 20% (25.47 μg )
Acuvue Oasys VE 30 % (23.95 μg)
Bimatoprost ReleasingVE-OASYS Lens
9
10
10 Patients tested
for safety wearing vitamin
E lenses and compared
to control lenses without
vitamin E
No adverse events reports
Pathology was normal
Visual acuity was not changed
2 Patients were
treated with Cosopt
No significant adverse reported
Transient irritation reported – likely due to the
benzalkonium preservative
IOP was significantly reduced (20mm HG) and remained reduced for up to 9 days after
removal of the drug/lens combination
Glaucoma Phase 1S tudy Resu l ts
11
10
12
14
16
18
20
22
24
0 50 100 150 200 250
SUBJECT 2
Series1 Series2
10
12
14
16
18
20
22
24
0 50 100 150 200 250
SUBJECT 1
Series1 Series2
Lenses were applied with (Light Green) and without (Dark green) drug on days 1 & 2
then removed after day 2. IOP was measured at time 0 and at regular intervals up to 9
days.
COSOPT Lens Reduces IOPUp to 9 Days Af te r One Dose
12
DATE MILESTONE
Q1 2020 Begin antibiotic lens manufacturing process
Q1 2020 Phase Ib Glaucoma studies
Q2 2020 IND Filed in EU for Cystinosis Phase I studies
Q2 2020 Patient Testing Antibiotic Lens
Q3 2020 Launch Antibiotic Lens
Q3 2020 Phase II Glaucoma studies
2020 Milestones
13
l Develop an effective drug-eluting CL to treat ocular surface disease
l Extensive patent portfolio covering the technology
l Covered by existing reimbursement methods
l Initial market: Bacterial corneal ulcers with extensive pipeline opportunities
l Raising $5M in financing to continue development and for product launch in 2020
Summary
13
